Search results for "therapeutic use"

showing 10 items of 104 documents

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted al…

2009

Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo T-cell-depleted allografts with declining donor TCC after day +60. A total of 13 patients received CD8(depl) DLI and 7 patients did not. All but one of the DLI patients converted to complete donor T-cell chimeras, whereas only one non-DLI patient converted spontaneously. DLI induced transient acute GVHD in five and extensive chronic GVHD in two patients. These data suggest the use of CD8(depl) DLI as an effective treatment for mixed TCC, partic…

CD4-Positive T-LymphocytesAntibodies NeoplasmLymphocytemedicine.medical_treatmentHematopoietic stem cell transplantation*Lymphocyte DepletionT-Lymphocyte SubsetsAlemtuzumabddc:616Transplantation Chimera/*immunologyHematopoietic Stem Cell TransplantationAntibodies MonoclonalHematologyMiddle Agedmedicine.anatomical_structureCD52 AntigenLymphocyte TransfusionAlemtuzumabmedicine.drug*GlycoproteinsAdultCD52T cellAntibodies Monoclonal/therapeutic useAntineoplastic AgentsCD4-Positive T-Lymphocytes/*transplantationAntibodies Monoclonal HumanizedLymphocyte DepletionAntigens CDAntigens NeoplasmmedicineAntibodies Neoplasm/therapeutic useHumans*Peripheral Blood Stem Cell TransplantationAgedCell ProliferationGlycoproteinsLymphocyte Transfusion/*methodsTransplantationPeripheral Blood Stem Cell TransplantationTransplantation Chimerabusiness.industryAntineoplastic Agents/therapeutic usemedicine.diseaseTransplantationGraft-versus-host disease*Antigens NeoplasmImmunology*Antigens CDbusinessCD8Bone marrow transplantation
researchProduct

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

2015

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate d…

COUNTRIESEstoniaMaleDrug Resistance Multiple Bacterial/drug effectsFluoroquinolones/pharmacologyGeneral Science & TechnologyAntitubercular Agents/therapeutic useRomania/epidemiologyAntitubercular Agentslcsh:MedicineDrug Resistance Multiple BacterialMD MultidisciplinaryTuberculosis Multidrug-ResistantHumansMULTIDRUG-RESISTANT TUBERCULOSISlcsh:ScienceLatvia/epidemiologyDemographyScience & TechnologyRomanialcsh:REstonia/epidemiologyLatviaMultidisciplinary SciencesCross-Sectional StudiesScience & Technology - Other Topicslcsh:QFemaleTuberculosis Multidrug-Resistant/drug therapyResearch ArticleFluoroquinolonesPLoS ONE
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial : Planned 10-Year Follow-up

2022

Abstract The CAPP2 trial investigated the long-term effects of aspirin and resistant starch on cancer incidence in patients with Lynch syndrome (LS). Participants with LS were randomized double-blind to 30 g resistant starch (RS) daily or placebo for up to 4 years. We present long-term cancer outcomes based on the planned 10-year follow-up from recruitment, supplemented by National Cancer Registry data to 20 years in England, Wales, and Finland. Overall, 463 participants received RS and 455 participants received placebo. After up to 20 years follow-up, there was no difference in colorectal cancer incidence (n = 52 diagnosed with colorectal cancer among those randomized to RS against n = 53…

Cancer ResearchLIVER3122 CancerstärkkelysCOLORECTAL-CANCERBUTYRATESDG 3 - Good Health and Well-beingasetyylisalisyylihappoHumansLynchin oireyhtymäpaksusuolisyöpäRISKIncidenceCOLON-CANCERResistant StarchColorectal Neoplasms/drug therapyCONSUMPTIONColorectal Neoplasms Hereditary NonpolyposisASPIRINMICROBIOMEOncologyAspirin/therapeutic useCELLSDIETARY FIBER INTAKE/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingsyöpätauditennaltaehkäisyseurantatutkimusColorectal Neoplasms Hereditary Nonpolyposis/complicationsColorectal NeoplasmsilmaantuvuusFollow-Up Studies
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer

2007

Paclitaxel plays an important role in the treatment of primary breast cancer. However, a substantial proportion of patients treated with paclitaxel does not appear to derive any benefit from this therapy. We performed a prospective study using tumour cells isolated from 50 primary breast carcinomas. Sensitivity of primary tumour cells to paclitaxel was determined in a clinically relevant range of concentrations (0.85-27.2 microg ml(-1) paclitaxel) using an ATP assay. Chemosensitivity data were used to study a possible association with immunohistochemically determined oestrogen and progesterone receptor (ER and PR) status, as well as histopathological parameters. Progesterone receptor (PR) m…

Cancer Researchmedicine.medical_specialtyReceptor StatusPaclitaxelmedicine.medical_treatmentBreast Neoplasmsprogesterone receptorchemistry.chemical_compoundBreast cancerInternal medicineProgesterone receptormedicineHumansRNA Messengerprimary tumour cellsChemotherapyBase SequenceDose-Response Relationship Drugbusiness.industryAntineoplastic AgentsPhytogenic/therapeutic use/Base Sequence/Breast Neoplasms/Pathology/DNA Probes/Dose-Response RelationshipDrug/Drug ResistanceNeoplasm/Humans/Immunohistochemistry/Paclitaxel/RNAMessenger/genetics/ReceptorsProgesterone/physiologyindividualized chemotherapymedicine.diseaseAntineoplastic Agents PhytogenicImmunohistochemistryIn vitrochemosensitivityEndocrinologyOncologyPaclitaxelchemistryDrug Resistance NeoplasmCancer researchImmunohistochemistryTranslational TherapeuticsDNA ProbesReceptors ProgesteroneBreast carcinomabusinessBritish Journal of Cancer
researchProduct

Influence of Chemical Enhancers and Iontophoresis on the In Vitro Transdermal Permeation of Propranolol: Evaluation by Dermatopharmacokinetics

2018

[EN] The aims of this study were to assess, in vitro, the possibility of administering propranolol transdermally and to evaluate the usefulness of the dermatopharmacokinetic (DPK) method in assessing the transport of drugs through stratum corneum, using propranolol as a model compound. Four chemical enhancers (decenoic and oleic acid, laurocapram, and R-(+)-limonene) and iontophoresis at two current densities, 0.25 and 0.5 mA/cm(2) were tested. R-(+)-limonene, and iontophoresis at 0.5 mA/cm(2) were proven to be the most efficient in increasing propranolol transdermal flux, both doubled the original propranolol transdermal flux. Iontophoresis was demonstrated to be superior than the chemical…

Drugdermatopharmacokineticsmedia_common.quotation_subjectChemical enhancerslcsh:RS1-441Pharmaceutical SciencePropanol - Uso terapéutico.02 engineering and technologyPropranololMedicamentos - Administración.030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medicaIonización.03 medical and health sciences0302 clinical medicineIonization.medicineStratum corneumpropranololDermatopharmacokineticsTransdermalmedia_commonchemical enhancersChromatographytransdermal administrationIontophoresisChemistryLaurocapramTransdermal administrationIontophoresisDrugs - Administration.Skin absorption.iontophoresisPermeation021001 nanoscience & nanotechnologyPropranololPropanol - Therapeutic use.In vitromedicine.anatomical_structurePropanol - Pharmacokinetics.Propanol - Farmacocinética.Absorción cutánea.0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.

2023

Background and ObjectivesCOVID-19–related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19.MethodsThis was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regress…

Fibrinolytic Agents/therapeutic useCerebral Hemorrhage/complicationsStroke/epidemiologyBrain Ischemia/complicationsTreatment OutcomeIschemic Stroke/epidemiologyCOVID-19/complicationsHumansCohort studiesEndovascular Procedures/adverse effectsRegistriesNeurology (clinical)610 Medicine & healthIntracranial Hemorrhages/etiologyThrombolytic Therapy/adverse effectsResearch Article
researchProduct

Anti-angiogenic drug loaded liposomes: Nanotherapy for early atherosclerotic lesions in mice.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190540 También participan en la elaboración de este artículo científico: Aracely Calatayud-Pascual, Alicia López-Castellano, Elena P. Albelda, Enrique García-España, Luis Martí-Bonmatí, Juan C. Frias y M. Teresa Albelda. Fumagillin-loaded liposomes were injected into ApoE-KO mice. The animals were divided into several groups to test the efficacy of this anti-angiogenic drug for early treatment of atherosclerotic lesions. Statistical analysis of the lesions revealed a decrease in the lesion size after 5 weeks of treatment.

Fluorescence-lifetime imaging microscopyPathologylcsh:MedicineAngiogenesis Inhibitors02 engineering and technology030204 cardiovascular system & hematologyVascular MedicineBiochemistryArteriosclerosis - Chemotherapy.Diagnostic RadiologyAteroesclerosis - Farmacoterapia.MiceWhite Blood Cells0302 clinical medicineAnimal CellsArteriosclerosis - Farmacoterapia.Medicine and Health SciencesArteries - Diseases - Treatment.Nanotechnologylcsh:ScienceAortaPhospholipidsmedia_commonMice KnockoutLiposomeDrug CarriersMultidisciplinarymedicine.diagnostic_testRadiology and Imaging021001 nanoscience & nanotechnologyMagnetic Resonance ImagingLipidsFatty Acids UnsaturatedEngineering and Technologymedicine.symptomCellular Structures and OrganellesCellular TypesAnatomy0210 nano-technologySesquiterpenesResearch ArticleDrugmedicine.medical_specialtyImaging Techniquesmedia_common.quotation_subjectImmune CellsImmunologyLiposomes.Research and Analysis MethodsLiposomas.Lesion03 medical and health sciencesText miningApolipoproteins ECyclohexanesDiagnostic Medicinemedicine.arteryFluorescence ImagingmedicineAnimalsArterias - Enfermedades - Tratamiento.VesiclesAortaBlood Cellsbusiness.industryMacrophageslcsh:RAnti angiogenicBiology and Life SciencesMagnetic resonance imagingCell BiologyAtherosclerosisFumagillin - Therapeutic use.Atherosclerosis - Chemotherapy.Disease Models AnimalFumagilina - Uso terapéutico.LiposomesCardiovascular AnatomyNanoparticlesBlood Vesselslcsh:QbusinessPloS one
researchProduct

Role of medical history and medication use in the aetiology of upper aerodigestive tract cancers in Europe: the ARCAGE study

2012

ABSTRACT Background The study aimed to investigate the role of medical history (skin warts, Candida albicans, herpetic lesions, heartburn, regurgitation) and medication use (for heartburn; for regurgitation; aspirin) in the aetiology of upper aerodigestive tract (UADT) cancer. Methods A multicentre (10 European countries) case–control study [Alcohol-Related CAncers and GEnetic susceptibility (ARCAGE) project]. Results There were 1779 cases of UADT cancer and 1993 controls. History of warts or C. albicans infection was associated with a reduced risk [odds ratio (OR) 0.80, 95% confidence interval (CI) 0.68–0.94 and OR 0.73, 95% CI 0.60–0.89, respectively] but there was no association with her…

GastroenterologyHeartburnCarcinoma Squamous Cell/etiologyRisk FactorsHerpesviridae Infections/complicationsEpidemiologyOdds RatioAspirinHeartburn/complicationsdigestive oral and skin physiologyCandidiasisHerpesviridae InfectionsHematologyMiddle AgedhumanitiesEuropeOncologyHead and Neck NeoplasmsCarcinoma Squamous CellAspirin/adverse effects/therapeutic useDisease SusceptibilityWartsmedicine.symptommedicine.drugAdultmedicine.medical_specialtyLaryngopharyngeal Reflux/complicationsYoung AdultInternal medicineLaryngopharyngeal Refluxmedicineotorhinolaryngologic diseasesHumansMedical historyHead and Neck Neoplasms/etiologyddc:613Warts/complicationsAspirinbusiness.industryaspirin use; epidemiology; gastroesophageal reflux; medical history; medication use; upperCase-control studyCancerHeartburnOdds ratiomedicine.diseasedigestive system diseasesCandidiasis/complicationsCase-Control StudiesEtiologybusiness
researchProduct